NOX.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 00:11):

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally...

Stats
Today's Volume	215 468
Average Volume	180 418
Market Cap	17.53M
EPS	$0 ( 2024-02-21 )
Next earnings date	( $0 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.500
ATR14	$0 (0.00%)

Noxopharm Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Noxopharm Ltd Financials

Annual	2023
Revenue:	$6.01M
Gross Profit:	$5.86M (97.43 %)
EPS:	$-0.0515

Q2	2023
Revenue:	$0
Gross Profit:	$-876.00 (0.00 %)
EPS:	$-0.00850

Q4	2023
Revenue:	$2.66M
Gross Profit:	$2.65M (99.59 %)
EPS:	$-0.0330

Q2	2023
Revenue:	$3.35M
Gross Profit:	$3.20M (95.71 %)
EPS:	$-0.0186

Financial Reports:

No articles found.

Noxopharm Ltd

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.